Company Filing History:
6 out of 7 
2 out of 25 
1 out of 12 Years Active: 2017-2025
Title: Taekyo Park: Innovator in Antibody-Drug Conjugates
Introduction
Taekyo Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 8 patents to his name, Park's work is recognized for its potential therapeutic applications.
Latest Patents
Among his latest patents, Park has developed substituted benzodiazepines as antibody-drug conjugates. This patent provides compounds and compositions that include substituted benzodiazepines of a specific class. Another notable patent involves antibody-drug conjugates comprising anti-B7-H3 antibodies. This disclosure relates to ADCs where one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker is designed to covalently connect active agents to the antibody. Furthermore, the patent discusses monoclonal antibodies and antigen-binding fragments that specifically target B7-H3, along with methods for their therapeutic, diagnostic, and prophylactic use.
Career Highlights
Throughout his career, Taekyo Park has worked with various companies, including Intocell, Inc. and Legochem Biosciences, Inc. His innovative research has positioned him as a key figure in the development of advanced therapeutic solutions.
Collaborations
Park has collaborated with notable colleagues such as Sunyoung Kim and Jongun Cho. Their combined expertise has contributed to the advancement of research in antibody-drug conjugates.
Conclusion
Taekyo Park's contributions to the field of biochemistry and his innovative patents in antibody-drug conjugates highlight his role as a leading inventor. His work continues to pave the way for new therapeutic approaches in medicine.